Key terms
About ALVR
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALVR news
Mar 19
1:35am ET
Maintaining a Hold: AlloVir’s Strategic Uncertainty and Financial Outlook
Feb 29
7:01pm ET
SHAREHOLDER ALERT: Potential Recovery for AlloVir, Inc. (ALVR) Investors
Feb 12
4:43pm ET
AlloVir Faces Delisting Risk, Considers Reverse Split to Comply
Jan 22
2:50pm ET
SHAREHOLDER ALERT: Potential Recovery for AlloVir, Inc. (ALVR) Investors
Jan 07
11:36am ET
Morgan Stanley lowers AlloVir to Underweight after discontinuations, job cuts
Jan 05
4:45pm ET
AlloVir downgraded to Underweight from Equal Weight at Morgan Stanley
Dec 29
7:10am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Karuna Therapeutics (KRTX), AlloVir (ALVR) and Top Glove Bhd (OtherTGLVY)
Dec 26
10:04am ET
Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
Dec 26
6:41am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), AlloVir (ALVR) and Bristol-Myers Squibb (BMY)
Dec 26
6:33am ET
AlloVir downgraded to Underperform from Buy at BofA
Dec 22
3:05pm ET
Hold Rating on AlloVir Following Posoleucel Program Discontinuation and Strategic Shift
Dec 22
2:49pm ET
AlloVir downgraded to Equal Weight from Overweight at Morgan Stanley
Dec 22
10:44am ET
AlloVir downgraded to Market Perform from Outperform at Leerink
Dec 22
9:31am ET
Nike downgraded, Waste Management upgraded: Wall Street’s top analyst calls
Dec 22
9:13am ET
Piper cuts AlloVir to Neutral after posoleucel development discontinued
Dec 22
9:07am ET
AlloVir downgraded to Neutral from Overweight at Piper Sandler
Dec 22
9:03am ET
AlloVir downgraded to Underweight from Overweight at JPMorgan
Dec 22
7:02am ET
AlloVir to discontinue three global Phase 3 posoleucel studies
Mar 19
10:51am ET
DEADLINE TODAY: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
Mar 19
8:54am ET
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVir
Mar 18
4:32pm ET
ALVR DEADLINE TOMORROW: ROSEN, A LEADING NATIONAL FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Mar 18
10:50am ET
DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
Mar 18
8:48am ET
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVir
Mar 16
2:00pm ET
ALVR DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Mar 16
8:47am ET
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVir
Mar 15
11:24am ET
TUESDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
Mar 14
1:27pm ET
ALVR DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Mar 14
7:23am ET
TUESDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
Mar 13
7:22am ET
TUESDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
Mar 13
5:51am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR
Mar 12
7:21am ET
7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
ALVR Financials
Key terms
Ad Feedback
ALVR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALVR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
